Inventor · disambiguated record
Michael N. Greco
Also filed as: GRECO MICHAEL · GRECO MICHAEL N · GRECO MICHAEL NICHOLAS
45 granted patents·10 pending applications·114 citations·filing 1990–2023
97Inventor score
Files withBETA PHARMA INC17JANSSEN PHARMACEUTICA NV15GRECO MICHAEL N11ORTHO MCNEIL PHARM INC5HAWKINS MICHAEL J3
Top patents by PatentIndex Score
55 records- 0187US9878994B22-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2015·Granted Jan 30, 2018·8 cites·32 claims
- 0285US10239864B22-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2018·Granted Mar 26, 2019·5 cites·20 claims
- 0385US7459461B2Phosphonic acid compounds as inhibitors of serine proteasesORTHO MCNEIL PHARM INC·Filed 2003·Granted Dec 2, 2008·17 cites·36 claims
- 0481US5491161APyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivativesJANSSEN PHARMACEUTICA NV·Filed 1995·Granted Feb 13, 1996·24 cites·4 claims
- 0580US7459444B2Inhibitors of chymaseJANSSEN PHARMACEUTICA NV·Filed 2005·Granted Dec 2, 2008·4 cites·58 claims
- 0679US9464055B2Quinoline derivatives useful as CB-1 inverse agonistsJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Oct 11, 2016·3 cites·16 claims
- 0777US6538017B2Aminopyrrolidine sulfonamides as serine protease inhibitorsORTHO MCNEIL PHARM INC·Filed 2002·Granted Mar 25, 2003·9 cites·24 claims
- 0877US5066656APharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivativesJANSSEN PHARMACEUTICA NV·Filed 1990·Granted Nov 19, 1991·18 cites·9 claims
- 0976US10590111B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2015·Granted Mar 17, 2020·2 cites·39 claims
- 1075US9266835B2Quinoline derivatives useful as CB-1 inverse agonistsJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Feb 23, 2016·2 cites·21 claims
- 1173US10118900B2Benzimidazole derivatives useful as CB-1 inverse agonistsJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Nov 6, 2018·1 cites·14 claims
- 1271US6765004B1Indoloazepines as vasopressin receptor antagonistsORTHO MCNEIL PHARM INC·Filed 2000·Granted Jul 20, 2004·6 cites·16 claims
- 1369US12187707B2Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereofBETA PHARMA INC·Filed 2021·Granted Jan 7, 2025·0 cites·13 claims
- 1469US8247599B2Phosphonic acid compounds as inhibitors of serine proteasesGRECO MICHAEL N·Filed 2008·Granted Aug 21, 2012·0 cites·11 claims
- 1569US8198440B2Phosphonic acid compounds as inhibitors of serine proteasesGRECO MICHAEL N·Filed 2008·Granted Jun 12, 2012·0 cites·3 claims
- 1669US8178673B2Phosphonic acid compounds as inhibitors of serine proteasesGRECO MICHAEL N·Filed 2008·Granted May 15, 2012·0 cites·9 claims
- 1767US8703957B2Phosphonic acid compounds as inhibitors of serine proteasesJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Apr 22, 2014·0 cites·5 claims
- 1867US8394804B2Phosphonic acid compounds as inhibitors of serine proteasesGRECO MICHAEL N·Filed 2008·Granted Mar 12, 2013·0 cites·4 claims
- 1967US2010048513A1Novel inhibitors of chymaseHAWKINS MICHAEL J·Filed 2008·Application pending·0 cites
- 2065US11180478B2Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereofBETA PHARMA INC·Filed 2018·Granted Nov 23, 2021·0 cites·15 claims
- 2164US8609888B2Phosphonic acid compounds as inhibitors of serine proteasesGRECO MICHAEL N·Filed 2012·Granted Dec 17, 2013·0 cites·11 claims
- 2262US8497373B2Phosphonic acid compounds as inhibitors of serine proteasesGRECO MICHAEL N·Filed 2012·Granted Jul 30, 2013·0 cites·5 claims
- 2362US8207338B2Phosphonic acid compounds as inhibitors of serine proteasesGRECO MICHAEL N·Filed 2010·Granted Jun 26, 2012·0 cites·1 claims
- 2461US11414401B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2020·Granted Aug 16, 2022·0 cites·7 claims
- 2561US8546358B2Method of treating asthmaHAWKINS MICHAEL J·Filed 2011·Granted Oct 1, 2013·0 cites·2 claims
- 2661US8461195B2Phosphonic acid compounds as inhibitors of serine proteasesGRECO MICHAEL N·Filed 2010·Granted Jun 11, 2013·0 cites·12 claims
- 2761US8304430B2Phosphonic acid compounds as inhibitors of serine proteasesGRECO MICHAEL N·Filed 2010·Granted Nov 6, 2012·0 cites·12 claims
- 2861US6710061B2Aminopyrrolidine sulfonamides as serine protease inhibitorsORTHO MCNEIL PHARAMCEUTICAL IN·Filed 2002·Granted Mar 23, 2004·1 cites·23 claims
- 2960US8212039B2Phosphonic acid compounds as inhibitors of serine proteasesGRECO MICHAEL N·Filed 2010·Granted Jul 3, 2012·0 cites·3 claims
- 3060US2025276968A18- and 6-substituted pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2023·Application pending·0 cites
- 3159US10844045B2Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereofBETA PHARMA INC·Filed 2017·Granted Nov 24, 2020·0 cites·23 claims
- 3258US2019031618A1Benzimidazole derivatives useful as cb-1 inverse agonistsJANSSEN PHARMACEUTICA NV·Filed 2018·Application pending·0 cites
- 3358US2025250286A1Fused pyrimidine derivatives as kras oncoprotein inhibitorsBETA PHARMA INC·Filed 2022·Application pending·0 cites
- 3456US11052086B22-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancersBETA PHARMA INC·Filed 2017·Granted Jul 6, 2021·0 cites·7 claims
- 3556US2009036409A1Novel inhibitors of chymaseHAWKINS MICHAEL J·Filed 2008·Application pending·0 cites
- 3654US11352341B22H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2019·Granted Jun 7, 2022·0 cites·19 claims
- 3754US2024140948A1Pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2022·Application pending·0 cites
- 3853US12258365B2Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2019·Granted Mar 25, 2025·0 cites·30 claims
- 3952US5457102APyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivativesJANSSEN PHARMACEUTICA NV·Filed 1994·Granted Oct 10, 1995·3 cites·8 claims
- 4052US2023099858A1Pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2021·Application pending·0 cites
- 4151US6890939B2Aminopyrrolidine sulfonamides as serine protease inhibitorsORTHO MCNEIL PHARM INC·Filed 2003·Granted May 10, 2005·0 cites·23 claims
- 4251US2024002365A1Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitorsBETA PHARMA INC·Filed 2021·Application pending·0 cites
- 4350US12390464B2Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitorsBETA PHARMA INC·Filed 2020·Granted Aug 19, 2025·0 cites·20 claims
- 4450US6630505B2Aminopyrrolidine sulfonamides as serine protease inhibitorsORTHO MCNEIL PHARM INC·Filed 2002·Granted Oct 7, 2003·0 cites·23 claims
- 4549US5888971AMacrocyclic peptides useful in the treatment of thrombin related disordersORTHO PHARMACEUTICAL CORP INC·Filed 1996·Granted Mar 30, 1999·11 cites·53 claims
- 4648US7872044B2Inhibitors of chymaseJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Jan 18, 2011·0 cites·19 claims
- 4746US9815790B2Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonistsJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Nov 14, 2017·0 cites·33 claims
- 4846US2022079944A12h-indazole derivatives as therapeutic agents for brain cancers and brain metastasesBETA PHARMA INC·Filed 2020·Application pending·0 cites
- 4942US9216998B2Tricyclic indole derivatives useful endothelial lipase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Dec 22, 2015·0 cites·16 claims
- 5041US8476302B2α-ketoamide derivatives useful endothelial lipase inhibitorsGRECO MICHAEL N·Filed 2011·Granted Jul 2, 2013·0 cites·17 claims
Showing the top 50 of 55 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →